Engystol® is produced in Germany and marketed by Biologische Heilmittel Heel GmbH for more than 60 years and marketed in Greece by A.S.K. Pharmaceutical, as an OTC medicine in tablet form.
The aim of treatment with Engystol® is to activate and support the body’s endogenous defense mechanisms and thus to strengthen the natural immune response in cases of upper respiratory viral infection, resulting in milder symptoms and shorter recovery times. Taken either preventively or at the first signs of a cold, Engystol® may prevent the development of acute symptoms(fever, bone aches, muscle aches).
Stimulation of the endogenous defence mechanisms with sympathetic action.
Reactant in all chronic diseases e.g. acute and chronic inflammation of the respiratory, hepatic and gastrointestinal system, catarrh of the upper respiratory tract, dyspnea, bronchial asthma, throbbing headache.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this patient information leaflet. You can also report side effects directly via the National Organization of Medicines, Mesogeion 284, GR-15562 Cholargos, Athens Tel: + 30 21 32040337 Website: http://www.eof.gr , http://www.kitrinikarta.gr .
By reporting side effects, you can help provide more information on the safety of this medicine.